

SUPPORTING INFORMATION

Silver-promoted dearomative [3 + 4] cycloaddition of anthranils with α -isocyanoacetates: access to benzodiazepines

Rui Shao,^{a†} Haixia Zhao,^{a†} Shumin Ding,^a Lianjie Li,^a Chen Chen,^a Jian Wang^{*a} and Yongjia Shang^{*a}

Key Laboratory of Functional Molecular Solids, Ministry of Education, Anhui Laboratory of Molecule-Based Materials (State Key Laboratory Cultivation Base), College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241002, P.R. China

Contents


I. General Information	2
II. Preparation of Starting Materials	2
III. General procedure for the cycloaddition reaction.....	3
IV. Optimization of Conditions	3
V. Characterization Data	5
VI. Copies of ¹ H and ¹³ C NMR Spectra.....	16
VII. X-ray Data.....	55
VIII. References	55

I. General Information

Unless otherwise specified, all reagents and starting materials were purchased from commercial sources and used as received. Solvents were used directly without further purification. The substrates of anthranils^[1-4] and α -isocyanoacetates^[5] were synthesized by reported methods. ¹H NMR (400 MHz), ¹H NMR (500 MHz) and ¹³C NMR (100 MHz) were registered on 400 M spectrometers. Chemical shifts were reported in units (ppm) by assigning CDCl₃ resonance in the ¹H spectrum as 7.26 ppm, CDCl₃ resonance in the ¹³C spectrum as 77.0 ppm, DMSO – D₆ resonance in the ¹H spectrum as 2.5 ppm, DMSO – D₆ resonance in the ¹³C spectrum as 39.52 ppm. All coupling constants (J values) were reported in Hertz (Hz). NMR analysis was carried out at 298 K unless noted otherwise HRMS was obtained on an ESI-LC-MS/MS spectrometer.


II. Preparation of Starting Materials

General procedure for the synthesis of anthranils¹



A round bottom flask equipped with a magnetic stirrer bar was charged with the substituted 2-nitroacylbenzene (3.00 mmol) in EtOAc–MeOH (1:1; 20 mL). SnCl₂·H₂O (9.00 mmol) was added and the reaction was stirred at room temperature for 24 h. The reaction was quenched by saturated NaHCO₃ (20 ml), and filtered. The aqueous phase was extracted with EtOAc (3×10 mL) and the organic portions combined, washed with H₂O (20 mL), saturated aqueous NaCl (20 mL), dried over Na₂SO₄, filtered and reduced in vacuo. The residue was purified by column chromatography (SiO₂, PE/EtOAc) to provide the title compound.

General Procedure for the Synthesis of α -isocyanoacetates²




To a solution of the ethyl isocyanoacetate (10 mmol) in THF (20.0 mL) and water (5.0 mL) was added potassium hydroxide (10 mmol), and the resultant mixture was stirred at room temperature for 5 h. The solvent was then removed in vacuum and the resultant salt was used without further purification.

In a 50 mL Schlenk flask were placed potassium 2-isocyanoacetate (10.6 mmol), benzyl bromide (10.9 mmol), and dimethylformamide (DMF, 10 mL), and the resulting mixture was stirred at 60 °C for 8 h. Then, DMF was removed under reduce pressure. To the residue was added water and extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na₂SO₄. After concentration in vacuo, the residue was purified by column chromatography on SiO₂ with hexane/AcOEt (4/1) to give

title compound (612 mg, 3.38 mmol).


III. General procedure for the cycloaddition reaction



To a mixture of Anthranilide (0.1 mmol), Ag_2O (50 mol%), $i\text{Pr}_2\text{NH}$ (0.1 mmol) in DCE (1 mL) was added of ethyl isocyanoacetate (0.5 mmol) in DCE (1 mL, analytical grade) via a syringe pump during a period of 4 h under Air at 25 °C, and then stir for another 2 h. The reaction mixture was quenched with water and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na_2SO_4 and evaporated under vacuo. The residue was purified by silica gel flash column chromatography to afford the product.

IV. Optimization of Conditions

Optimization of the reaction conditions^a




entry	$[\text{Ag}]$	ligand	base	solvent	Yield(%)
1	Ag_2O	PPh_3	$i\text{Pr}_2\text{NH}$	DCE	19
2 ^b	Ag_2O	PPh_3	$i\text{Pr}_2\text{NH}$	DCE	7
3	Ag_2O	PCy_3	$i\text{Pr}_2\text{NH}$	DCE	10

4	Ag ₂ O	Tris(o-anisyl)phosphine	^t Pr ₂ NH	DCE	9
5	Ag ₂ O	dppb	^t Pr ₂ NH	DCE	NR
6	Ag ₂ O	BINAP	^t Pr ₂ NH	DCE	12
7	Ag ₂ O	L1	^t Pr ₂ NH	DCE	57
8	Ag ₂ O	L2	^t Pr ₂ NH	DCE	65
9	Ag ₂ O	L3	^t Pr ₂ NH	DCE	45
10	Ag ₂ O	L4	^t Pr ₂ NH	DCE	38
11	AgF	L2	^t Pr ₂ NH	DCE	49
12	AgOAc	L2	^t Pr ₂ NH	DCE	37
13	Ag ₃ PO ₄	L2	^t Pr ₂ NH	DCE	43
14	Ag ₂ CO ₃	L2	^t Pr ₂ NH	DCE	56
15	/	L2	^t Pr ₂ NH	DCE	0
16	Ag ₂ O	L2	Bn ₂ NH	DCE	36
17	Ag ₂ O	L2	DIPEA	DCE	38
18	Ag ₂ O	L2	K ₂ CO ₃	DCE	21
19	Ag ₂ O	L2	NaOAc	DCE	27
20	Ag ₂ O	L2	Amantadine	DCE	50
21	Ag ₂ O	L2	^t Pr ₂ NH	Dioxane	33
22	Ag ₂ O	L2	^t Pr ₂ NH	THF	24
23	Ag ₂ O	L2	^t Pr ₂ NH	Toluene	44
24	Ag ₂ O	L2	^t Pr ₂ NH	MeCN	21
25	Ag ₂ O	L2	^t Pr ₂ NH	Ether	30
26	Ag ₂ O	L2	^t Pr ₂ NH	MTBE	43
27	Ag ₂ O	L2	^t Pr ₂ NH	PhCl	51
28 ^c	Ag ₂ O	L2	^t Pr ₂ NH	DCE	73
29 ^c	Ag ₂ O	/	^t Pr ₂ NH	DCE	55
30 ^{c,d}	Ag ₂ O	/	^t Pr ₂ NH	DCE	79
31 ^{c,d}	Ag ₂ O	/	^t Pr ₂ NH (0.5equiv)	DCE	57
32 ^{c,d}	Ag ₂ O	/	^t Pr ₂ NH (1.5equiv)	DCE	72
33 ^{c,d}	Ag ₂ O	/	^t Pr ₂ NH (2.0equiv)	DCE	63
34 ^{c,d,e}	Ag ₂ O	/	^t Pr ₂ NH	DCE	53
35 ^{c,d,f}	Ag ₂ O	/	^t Pr ₂ NH	DCE	75


^aReaction conditions: **1a** (0.1 mmol), **2a** (0.3 mmol), [Ag] (15 mol %), L (30 mol %), base (0.1 mmol), solvent (2.0 mL). A solution of **2a** in solvent (1 mL) was added slowly *via* a syringe pump in 4 h, and the reaction mixture was stirred for further 2 h at room temperature under air. Yields of isolated products. ^bPPh₃ (60 mol%). ^c**2a** (0.5 mmol). ^dAg₂O (50 mol%) and without ligand. ^e**2a** was added in one portion. ^fUnder Ar.

V. Characterization Data




4-chlorobenzo[c]isoxazole (1b)

Following the general procedure for the synthesis of anthranils: ^1H NMR (400 MHz, Chloroform-*d*) δ 9.21 (d, $J = 1.1$ Hz, 1H), 8.00 – 7.38 (m, 1H), 7.25 (dd, $J = 9.0, 6.9$ Hz, 1H), 7.02 (d, $J = 6.9$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 156.58, 154.87, 131.16, 125.28, 123.29, 119.41, 113.79. HRMS (ESI) Calc. for $\text{C}_7\text{H}_5\text{ClNO}^+$ $[\text{M}+\text{H}]^+$: 154.0054; found: 154.0055.




3-methylbenzo[c]isoxazole (1ae)

Following the general procedure for the synthesis of anthranils: ^1H NMR (400 MHz, Chloroform-*d*) δ 7.49 (dd, $J = 9.1, 2.8$ Hz, 1H), 7.42 (ddd, $J = 8.8, 2.8, 1.4$ Hz, 1H), 7.32 – 7.19 (m, 1H), 7.00 – 6.84 (m, 1H), 2.76 (d, $J = 1.5$ Hz, 3H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 165.74, 157.04, 130.84, 122.77, 119.90, 115.62, 114.79, 11.96. HRMS (ESI) Calc. for $\text{C}_8\text{H}_8\text{NO}^+$ $[\text{M}+\text{H}]^+$: 134.0600; found: 134.0592.




3-(trifluoromethyl)benzo[c]isoxazole (1af)

Following the general procedure for the synthesis of anthranils: ^1H NMR (400 MHz, Chloroform-*d*) δ 7.70 (dd, $J = 9.3, 1.1$ Hz, 1H), 7.66 – 7.59 (m, 1H), 7.41 (dd, $J = 9.2, 6.4$ Hz, 1H), 7.23 (dd, $J = 8.9, 6.4$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 156.94, 151.71 (q, $J = 42.8$ Hz), 131.49, 127.53, 118.87 (q, $J = 268.1$ Hz), 117.99, 116.79, 115.60. ^{19}F NMR (377 MHz, CDCl_3) δ -61.98. HRMS (ESI) Calc. for $\text{C}_8\text{H}_5\text{F}_3\text{NO}^+$ $[\text{M}+\text{H}]^+$: 188.0318; found: 188.0324.




8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepin-4-yl propionate (3a)

21.0 mg, 79% yield, yellow solid, MP = 199 – 200 °C, ^1H NMR (400 MHz, DMSO-*d*₆) δ 9.03 (d, $J = 2.2$ Hz, 1H), 7.54 (t, $J = 2.1$ Hz, 1H), 7.22 (d, $J = 8.3$ Hz, 1H), 7.05 (dd, $J = 8.3, 2.1$ Hz, 1H), 6.99 (d, $J = 2.1$ Hz, 1H), 6.85 (d, $J = 1.8$ Hz, 1H), 4.25 (q, $J = 7.1$ Hz, 2H), 1.29 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, DMSO) δ 162.7, 160.6, 140.3, 134.4, 132.4, 127.4, 123.5, 123.2, 119.6, 118.4, 61.9, 13.9. HRMS (ESI) Calc. for $\text{C}_{12}\text{H}_{12}\text{ClN}_2\text{O}_3^+$ $[\text{M}+\text{H}]^+$: 267.0531; found: 267.0541.




ethyl 6-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3b)

12.5 mg, 47% yield, yellow solid, MP = 186 – 187 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.11 (d, *J* = 2.3 Hz, 1H), 7.85 (t, *J* = 2.0 Hz, 1H), 7.28 (t, *J* = 8.0 Hz, 1H), 7.18 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.12 (d, *J* = 1.7 Hz, 1H), 6.96 (dt, *J* = 8.1, 0.9 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.29 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.66, 141.42, 132.78, 131.47, 129.51, 124.42, 122.95, 119.86, 116.41, 62.16, 14.03. HRMS (ESI) Calc. for C₁₂H₁₂ClN₂O₃⁺ [M+H]⁺: 267.0531; found: 267.0523.




ethyl 7-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3c)

13.5 mg, 51% yield, yellow solid, MP = 172 – 173 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 3.0 Hz, 1H), 7.51 (s, 1H), 7.40 – 7.23 (m, 2H), 6.94 (t, *J* = 6.4 Hz, 1H), 6.87 (d, *J* = 3.4 Hz, 1H), 4.44 – 4.08 (m, 2H), 1.41 – 1.17 (m, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.7, 161.2, 138.0, 130.0, 129.9, 128.4, 127.4, 126.7, 122.0, 118.1, 62.1, 14.0. HRMS (ESI) Calc. for C₁₂H₁₂ClN₂O₃⁺ [M+H]⁺: 267.0531; found: 267.0530.



ethyl 9-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3d)


9.8 mg, 37% yield, yellow solid, MP = 145 – 146 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.98 (d, *J* = 2.5 Hz, 1H), 7.90 (t, *J* = 2.1 Hz, 1H), 7.48 (dt, *J* = 8.0, 1.1 Hz, 1H), 7.26 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.15 – 7.08 (m, 1H), 7.05 (d, *J* = 1.8 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.7, 161.9, 134.4, 130.5, 129.4, 129.2, 128.4, 125.2, 124.3, 119.5, 62.1, 14.0. HRMS (ESI) Calc. for C₁₂H₁₂ClN₂O₃⁺ [M+H]⁺: 267.0531; found: 267.0538.



2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepin-4-yl propionate (3e)

12.1 mg, 52% yield, yellow solid· MP = 150 – 151 °C, ¹H NMR (400 MHz, Chloroform-*d*) δ 7.24 – 7.16 (m, 1H), 7.08 – 6.96 (m, 2H), 6.89 (s, 1H), 6.84 (d, *J* = 1.8 Hz, 1H), 6.69 (d, *J* = 8.0 Hz, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.9, 161.3, 138.0, 131.1, 130.8, 126.7, 124.4, 124.1, 120.0, 119.2, 62.4, 14.2.


HRMS (ESI) Calc. for C₁₂H₁₃N₂O₃⁺ [M+H]⁺: 233.0921; found: 233.0930.



ethyl 7-fluoro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3f)

13.4 mg, 54% yield, yellow solid· MP = 161 – 162 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.94 (d, *J* = 2.3 Hz, 1H), 7.46 (d, *J* = 2.4 Hz, 1H), 7.22 – 7.03 (m, 2H), 6.94 (d, *J* = 5.1 Hz, 1H), 6.87 (d, *J* = 1.8 Hz, 1H), 4.25 (q, *J* = 7.1 Hz, 2H), 1.28 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.8, 161.8, 159.4, 135.5, 128.5, 126.8 (d, *J* = 8.1 Hz), 122.1 (d, *J* = 8.6 Hz), 118.4, 117.0 (d, *J* = 22.8 Hz), 116.4 (d, *J* = 23.5 Hz), 62.1, 14.0. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -120.8.


HRMS (ESI) Calc. for C₁₂H₁₂FN₂O₃⁺ [M+H]⁺: 251.0826; found: 251.0822.



8-fluoro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepin-4-yl propionate (3g)

14.9 mg, 60% yield, yellow solid· MP = 156 – 157 °C, ¹H NMR (400 MHz, Chloroform-*d*) δ 7.77 (s, 1H), 6.97 (dd, *J* = 8.6, 6.2 Hz, 1H), 6.92 (s, 1H), 6.77 (d, *J* = 1.9 Hz, 1H), 6.72 – 6.63 (m, 1H), 6.50 (dd, *J* = 9.7, 2.5 Hz, 1H), 4.32 (q, *J* = 7.1 Hz, 2H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 165.3, 162.8, 160.7, 140.0 (d, *J* = 10.3 Hz), 132.8 (d, *J* = 9.9 Hz), 125.8, 120.5 (d, *J* = 3.2 Hz), 118.5, 110.9 (d, *J* = 21.7 Hz), 107.4 (d, *J* = 25.4 Hz), 62.5, 14.18. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -109.2.


HRMS (ESI) Calc. for C₁₂H₁₂FN₂O₃⁺ [M+H]⁺: 251.0826; found: 251.0823.



7-bromo-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepin-4-yl propionate (3h)

17.6 mg, 57% yield, yellow solid· MP = 189 – 190 °C, ¹H NMR (400 MHz, Chloroform-*d*) δ 7.29 (dd, *J* = 8.5, 2.3 Hz, 1H), 7.17 (d, *J* = 2.3 Hz, 1H), 6.92 (s, 2H), 6.74 (d, *J* = 1.8 Hz, 1H), 6.57 (d, *J* = 8.5 Hz, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.6, 160.5, 136.8, 133.3, 133.3, 127.6, 126.5, 121.5, 117.4, 116.8, 62.7, 14.1.


HRMS (ESI) Calc. for C₁₂H₁₂BrN₂O₃⁺ [M+H]⁺: 311.0026; found: 311.0027.



ethyl 8-bromo-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3i)

21.3 mg, 69% yield, yellow solid. MP = 185 – 186 °C, ¹H NMR (400 MHz, Chloroform-*d*) δ 7.12 (d, *J* = 1.9 Hz, 1H), 7.10 (d, *J* = 2.0 Hz, 1H), 6.94 (s, 1H), 6.90 – 6.85 (m, 2H), 6.76 (d, *J* = 1.8 Hz, 1H), 4.33 (q, *J* = 7.2 Hz, 2H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.7, 160.4, 138.9, 132.2, 127.2, 126.8, 124.2, 123.4, 122.8, 118.1, 62.6, 14.1.


HRMS (ESI) Calc. for C₁₂H₁₂BrN₂O₃⁺ [M+H]⁺: 311.0026; found: 311.0029.



ethyl 8-cyano-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3j)

19.5 mg, 76% yield, yellow solid. MP = 193 – 194 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.19 (s, 1H), 7.76 (s, 1H), 7.44-7.38 (m 2H), 7.26 (d, *J* = 2.7 Hz, 1H), 6.87 (d, *J* = 2.9 Hz, 1H), 4.27 (td, *J* = 7.2, 2.5 Hz, 2H), 1.30 (qd, *J* = 7.0, 6.3, 2.9 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.5, 160.5, 139.5, 131.8, 129.8, 129.6, 126.9, 123.1, 118.3, 117.4, 112.1, 62.3, 14.0.


HRMS (ESI) Calc. for C₁₃H₁₂N₃O₃⁺ [M+H]⁺: 258.0873; found: 258.0872.



4-ethyl 8-methyl 2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4,8-dicarboxylate (3k)

21.4 mg, 74% yield, yellow solid. MP = 178 – 179 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.14 (d, *J* = 2.2 Hz, 1H), 7.61 (t, *J* = 2.0 Hz, 1H), 7.58 – 7.50 (m, 2H), 7.31 (d, *J* = 8.0 Hz, 1H), 6.88 (d, *J* = 1.8 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 165.4, 162.6, 160.8, 139.1, 131.1, 130.9, 129.4, 129.0, 123.9, 120.9, 117.8, 62.1, 52.3, 13.9.


HRMS (ESI) Calc. for C₁₄H₁₅N₂O₅⁺ [M+H]⁺: 291.0975; found: 251.0984.



ethyl 2-oxo-8-phenyl-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3l)

17.2 mg, 56% yield, yellow solid· MP = 214 – 215 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.98 (d, *J* = 2.3 Hz, 1H), 7.61 (dd, *J* = 8.2, 1.4 Hz, 2H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.44 – 7.35 (m, 2H), 7.30 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.28 – 7.23 (m, 2H), 6.90 (d, *J* = 1.7 Hz, 1H), 4.26 (q, *J* = 7.1 Hz, 2H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.9, 161.0, 142.2, 139.4, 138.8, 131.5, 129.0, 128.0, 127.0, 126.3, 123.7, 121.7, 118.9, 118.3, 61.9, 14.0.


HRMS (ESI) Calc. for C₁₈H₁₇N₂O₃⁺ [M+H]⁺:309.1234; found: 309.1226.



ethyl 2-oxo-8-(*p*-tolyl)-2,3-dihydro-1*H*-benzo[*d*][1,3]diazepine-4-carboxylate (3m)

19.6 mg, 61% yield, yellow solid· MP = 205 – 206 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.95 (d, *J* = 2.3 Hz, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.40 (d, *J* = 2.1 Hz, 1H), 7.31 – 7.25 (m, 3H), 7.27 – 7.21 (m, 2H), 6.89 (d, *J* = 1.7 Hz, 1H), 4.26 (q, *J* = 7.0 Hz, 2H), 2.34 (s, 3H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 163.3, 161.4, 142.6, 139.9, 138.0, 136.4, 132.0, 130.1, 127.3, 126.6, 123.8, 121.8, 119.5, 118.4, 62.4, 21.1, 14.5.


HRMS (ESI) Calc. for C₁₉H₁₉N₂O₃⁺ [M+H]⁺:323.1390; found: 323.1392.



ethyl 8-(4-chlorophenyl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*][1,3]diazepine-4-carboxylate (3n)

21.6 mg, 63% yield, yellow solid· MP = 208 – 209 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.97 (d, *J* = 2.3 Hz, 1H), 7.68 – 7.60 (m, 2H), 7.57 – 7.48 (m, 2H), 7.44 (t, *J* = 2.1 Hz, 1H), 7.31 (dd, *J* = 8.0, 1.8 Hz, 1H), 7.30 – 7.21 (m, 2H), 6.90 (d, *J* = 1.8 Hz, 1H), 4.26 (q, *J* = 7.1 Hz, 2H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 163.3, 161.4, 141.2, 139.9, 138.1, 133.3, 132.1, 129.5, 128.6, 127.7, 124.5, 122.1, 119.3, 118.6, 62.4, 14.5.


HRMS (ESI) Calc. for C₁₈H₁₆ClN₂O₃⁺ [M+H]⁺:343.0844; found: 343.0849.



methyl 8-chloro-2-oxo-2,3-dihydro-1*H*-benzo[*d*][1,3]diazepine-4-carboxylate (3o)

12.3 mg, 49% yield, yellow solid· MP = 175 – 176 °C, ¹H NMR (400 MHz, Chloroform-*d*) δ 7.33 (s, 1H), 7.00 – 6.88 (m, 3H), 6.77 (d, *J* = 1.8 Hz, 1H), 6.73 (t, *J* = 1.3 Hz, 1H), 3.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.2, 160.3, 138.9, 136.4, 132.1, 126.4, 124.3, 122.9, 120.0, 118.4, 53.2.


HRMS (ESI) Calc. for $C_{11}H_{10}ClN_2O_3^+$ $[M+H]^+$:253.0374; found: 253.0376.



tert-butyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3p)

19.9 mg, 68% yield, yellow solid. MP = 161 – 162 °C, 1H NMR (500 MHz, DMSO- d_6) δ 9.02 (d, J = 2.7 Hz, 1H), 7.38 (t, J = 2.1 Hz, 1H), 7.18 (d, J = 8.3 Hz, 1H), 7.03 (dd, J = 8.3, 2.0 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 6.75 (d, J = 1.6 Hz, 1H), 1.50 (s, 9H). ^{13}C NMR (100 MHz, DMSO) δ 161.8, 160.7, 140.3, 134.3, 132.4, 128.4, 123.7, 123.3, 119.6, 117.8, 82.7, 27.6.


HRMS (ESI) Calc. for $C_{14}H_{16}ClN_2O_3^+$ $[M+H]^+$:295.0844; found: 295.0843.



cyclohexylmethyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3q)

19.0 mg, 57% yield, yellow solid, MP = 167 – 168 °C, 1H NMR (500 MHz, DMSO- d_6) δ 9.04 (d, J = 2.5 Hz, 1H), 7.75 – 7.38 (m, 1H), 7.22 (dd, J = 8.6, 5.1 Hz, 1H), 7.03 (dt, J = 8.2, 3.3 Hz, 1H), 6.99 (d, J = 2.2 Hz, 1H), 6.84 (d, J = 3.9 Hz, 1H), 4.01 (d, J = 6.4 Hz, 2H), 1.82 – 1.52 (m, 6H), 1.33 – 1.08 (m, 4H), 0.99 (t, J = 12.2 Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 162.8, 160.7, 140.4, 134.5, 132.6, 127.3, 123.6, 123.3, 119.7, 118.5, 70.6, 29.0, 25.9, 25.2.


HRMS (ESI) Calc. for $C_{17}H_{20}ClN_2O_3^+$ $[M+H]^+$:335.1157; found:335.1158.



benzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3r)

23.2 mg, 71% yield, yellow solid. MP = 209 – 210 °C, 1H NMR (500 MHz, DMSO- d_6) δ 9.04 (d, J = 2.3 Hz, 1H), 7.62 (d, J = 2.1 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.41 (t, J = 7.3 Hz, 2H), 7.38 – 7.34 (m, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.04 (dd, J = 8.3, 2.2 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 6.91 (d, J = 1.9 Hz, 1H), 5.28 (s, 2H). ^{13}C NMR (100 MHz, DMSO) δ 163.13, 161.24, 140.88, 136.02, 135.05, 133.03, 129.00, 128.77, 128.65, 127.71, 123.99, 123.72, 120.14, 119.49, 67.72.


HRMS (ESI) Calc. for $C_{17}H_{14}ClN_2O_3^+$ $[M+H]^+$:329.0687; found:329.0681.



2-methylbenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3s)

22.5 mg, 66% yield, yellow solid· MP = 191 – 192 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.05 (d, *J* = 2.3 Hz, 1H), 7.67 – 7.48 (m, 1H), 7.39 (d, *J* = 7.4 Hz, 1H), 7.29-7.19 (m, 4H), 7.04-7.01 (m, 1H), 6.99 (d, *J* = 2.1 Hz, 1H), 6.87 (d, *J* = 1.9 Hz, 1H), 5.29 (s, 2H), 2.34 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.6, 160.8, 140.4, 136.9, 134.6, 133.4, 132.6, 130.2, 129.2, 128.6, 127.2, 125.9, 123.5, 123.2, 119.6, 118.9, 65.8, 18.5.


HRMS (ESI) Calc. for C₁₈H₁₆ClN₂O₃⁺ [M+H]⁺:343.0844; found: 343.0843.



3-methylbenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3t)

18.1 mg, 53% yield, yellow solid· MP = 186 – 187 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.2 Hz, 1H), 7.66 – 7.58 (m, 1H), 7.34 – 7.20 (m, 4H), 7.17 (d, *J* = 7.5 Hz, 1H), 7.04 (dt, *J* = 8.3, 1.8 Hz, 1H), 6.99 (d, *J* = 2.1 Hz, 1H), 6.90 (d, *J* = 1.9 Hz, 1H), 5.24 (s, 2H), 2.32 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.6, 160.7, 140.4, 137.7, 135.4, 134.5, 132.5, 128.9, 128.8, 128.4, 127.2, 125., 123.5, 123.2, 119.6, 118.9, 67.3, 20.9.


HRMS (ESI) Calc. for C₁₈H₁₆ClN₂O₃⁺ [M+H]⁺:343.0844; found:343.0842.



4-methylbenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3u)

19.8 mg, 58% yield, yellow solid· MP = 185 – 186 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.04 (s, 1H), 7.58 (s, 1H), 7.44 – 7.32 (m, 2H), 7.22 (tt, *J* = 7.4, 4.9, 4.3 Hz, 3H), 7.10 – 6.98 (m, 2H), 6.89 (d, *J* = 2.6 Hz, 1H), 5.23 (d, *J* = 2.9 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 162.7, 160.8, 140.4, 137.8, 134.6, 132.6, 132.5, 129.1, 128.4, 127.3, 123.5, 123.3, 119.7, 118.9, 67.3, 20.8.


HRMS (ESI) Calc. for C₁₈H₁₆ClN₂O₃⁺ [M+H]⁺:343.0844; found: 343.0839.



4-(tert-butyl)benzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3v)

23.4 mg, 61% yield, yellow solid· MP = 196 – 197 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (s, 1H), 7.59 (s, 1H), 7.48 – 7.33 (m, 4H), 7.30 – 7.18 (m, 1H), 7.04 (dt, *J* = 8.3, 2.4 Hz, 1H), 6.99 (d, *J* = 2.0 Hz, 1H), 6.89 (d, *J* = 2.3 Hz, 1H), 5.23 (d, *J* = 2.1 Hz, 2H), 1.27 (d, *J* = 2.4 Hz, 9H). ¹³C NMR (100 MHz, DMSO) δ 162.7, 160.8, 150.9, 140.4, 134.6, 132.6, 128.3, 128.2, 127.3, 125.4, 125.3, 123.6, 123.3, 119.7, 119.0, 67.2, 34.4, 31.1, 31.1.


HRMS (ESI) Calc. for C₂₁H₂₀ClN₂O₃⁻ [M-H]⁻:383.1168; found:383.1155.



3-methoxybenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3w)

20.0 mg, 56% yield, yellow solid· MP = 190 – 191 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.2 Hz, 1H), 7.62 (d, *J* = 2.2 Hz, 1H), 7.31 (d, *J* = 8.2 Hz, 1H), 7.23 (d, *J* = 8.3 Hz, 1H), 7.08 – 6.98 (m, 4H), 6.95 – 6.89 (m, 2H), 5.24 (s, 2H), 3.76 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.6, 160.8, 159.3, 140.4, 137.0, 134.6, 132.5, 129.6, 127.2, 123.5, 123.2, 120.2, 119.6, 119.1, 113.7, 67.1, 55.1.


HRMS (ESI) Calc. for C₁₈H₁₆ClN₂O₄⁺ [M+H]⁺:359.0793; found:359.0791.



[1,1'-biphenyl]-4-ylmethyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3x)

21.4 mg, 53% yield, yellow solid, MP = 196 – 197 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.05 (d, *J* = 2.3 Hz, 1H), 7.74 – 7.66 (m, 4H), 7.64 (d, *J* = 2.2 Hz, 1H), 7.55 (d, *J* = 8.2 Hz, 2H), 7.47 (t, *J* = 7.7 Hz, 2H), 7.38 (d, *J* = 7.4 Hz, 1H), 7.24 (d, *J* = 8.3 Hz, 1H), 7.05 (dd, *J* = 8.3, 2.1 Hz, 1H), 7.00 (d, *J* = 2.1 Hz, 1H), 6.94 (d, *J* = 1.7 Hz, 1H), 5.33 (s, 2H). ¹³C NMR (100 MHz, DMSO) δ 162.8, 160.9, 140.5, 140.3, 139.8, 134.8, 134.7, 132.6, 129.1, 129.0, 127.7, 127.3, 126.9, 126.8, 123.6, 123.3, 119.7, 119.2, 67.1


HRMS (ESI) Calc. for C₂₃H₁₆ClN₂O₃⁻ [M-H]⁻:403.0855; found: 403.0860.



4-fluorobenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3y)

17.9 mg, 52% yield, yellow solid, MP = 189 – 190 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.03 (d, *J* = 2.2 Hz, 1H), 7.62 (s, 1H), 7.56 – 7.49 (m, 2H), 7.28 – 7.20 (m, 3H), 7.04 (dd, *J* = 8.3, 2.1 Hz, 1H), 6.99 (d, *J* = 2.1 Hz, 1H), 6.90 (s, 1H), 5.26 (s, 1H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.3, 162.7, 160.9, 160.8, 140.5, 134.6, 132.6, 131.9, 131.8, 130.7 (d, *J* = 8.4 Hz), 127.3, 123.4 (d, *J* = 25.3 Hz), 119.4 (d, *J* = 57.7 Hz), 115.4 (d, *J* = 21.4 Hz), 66.6. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -113.7.


HRMS (ESI) Calc. for C₁₇H₁₃ClF₁N₂O₃⁺ [M+H]⁺:347.0593; found:347.0598.



2-chlorobenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3z)

26.1 mg, 72% yield, yellow solid, MP = 195 – 196 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.05 (d, *J* = 2.9 Hz, 1H), 7.69 – 7.58 (m, 2H), 7.53 (ddd, *J* = 9.2, 5.2, 2.3 Hz, 1H), 7.45 – 7.37 (m, 2H), 7.24 (d, *J* = 8.5 Hz, 1H), 7.08 – 6.97 (m, 2H), 6.92 (d, *J* = 2.0 Hz, 1H), 5.36 (s, 1H). ¹³C NMR (100 MHz, DMSO) δ 162.9, 161.2, 140.9, 135.1, 133.3, 133.1, 133.0, 130.9, 130.7, 129.9, 127.9, 127.4, 123.9, 123.7, 120.1, 119.7, 65.1.


HRMS (ESI) Calc. for C₁₇H₁₁Cl₂N₂O₃⁻ [M-H]⁻:361.0152; found:361.0157.



3-chlorobenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3aa)

30.7 mg, 85% yield, yellow solid, MP = 179 – 180 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.3 Hz, 1H), 7.68 (t, *J* = 1.9 Hz, 1H), 7.56 (dd, *J* = 2.0, 0.9 Hz, 1H), 7.44 (d, *J* = 1.3 Hz, 3H), 7.24 (d, *J* = 8.3 Hz, 1H), 7.05 (dd, *J* = 8.3, 2.1 Hz, 1H), 7.00 (d, *J* = 2.2 Hz, 1H), 6.94 (d, *J* = 1.7 Hz, 1H), 5.28 (s, 2H). ¹³C NMR (100 MHz, DMSO) δ 162.6, 160.8, 140.5, 138.1, 134.6, 133.1, 132.6, 130.5, 128.2, 128.0, 127.2, 126.8, 126.8, 123.5, 123.3, 119.7, 119.3, 66.4.


HRMS (ESI) Calc. for C₁₇H₁₃Cl₂N₂O₃⁺ [M+H]⁺:363.0298; found: 363.0305.



2,6-dichlorobenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3ab)

34.3 mg, 87% yield, yellow solid, MP = 215 – 216 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.3 Hz, 1H), 7.63 (t, *J* = 2.0 Hz, 1H), 7.60 – 7.55 (m, 2H), 7.48 (dd, *J* = 8.8, 7.3 Hz, 1H), 7.20 (d, *J* = 8.3 Hz, 1H), 7.02 (dd, *J* = 8.3, 2.1 Hz, 1H), 6.99 (d, *J* = 2.1 Hz, 1H), 6.80 (d, *J* = 1.7 Hz, 1H), 5.48 (s, 2H). ¹³C NMR (100 MHz, DMSO) δ 162.4, 160.8, 140.4, 136.1, 134.6, 132.6, 131.8, 130.4, 128.8, 126.8, 123.3, 123.2, 119.6, 119.3, 62.4.


HRMS (ESI) Calc. for C₁₇H₁₂Cl₃N₂O₃⁺ [M+H]⁺:396.9908; found:396.9899.



4-bromobenzyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3ac)

30.7 mg, 76% yield, yellow solid, MP = 205 – 206 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.3 Hz, 1H), 7.64 (d, *J* = 2.1 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.46 – 7.40 (m, 2H), 7.23 (d, *J* = 8.3 Hz, 1H), 7.05 (dd, *J* = 8.3, 2.2 Hz, 1H), 6.99 (d, *J* = 2.2 Hz, 1H), 6.91 (d, *J* = 1.8 Hz, 1H), 5.25 (s, 2H). ¹³C NMR (100 MHz, DMSO) δ 163.0, 161.2, 140.8, 135.4, 135.0, 132.9, 131.8, 130.8, 127.5, 123.9, 123.6, 121.9, 120.1, 119.6, 66.8.


HRMS (ESI) Calc. for C₁₇H₁₁BrClN₂O₃⁻ [M-H]⁻:404.9647; found:404.9647.



naphthalen-2-ylmethyl 8-chloro-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (3ad)

28.3 mg, 75% yield, yellow solid, MP = 207 – 208 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.3 Hz, 1H), 8.01 – 7.98 (m, 1H), 7.98 – 7.89 (m, 3H), 7.65 (t, *J* = 2.1 Hz, 1H), 7.59 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.56 – 7.51 (m, 2H), 7.23 (d, *J* = 8.3 Hz, 1H), 7.03 (dd, *J* = 8.3, 2.1 Hz, 1H), 6.99 (d, *J* = 2.1 Hz, 1H), 6.94 (d, *J* = 1.7 Hz, 1H), 5.44 (s, 2H). ¹³C NMR (100 MHz, DMSO) δ 162.7, 160.8, 140.4, 134.6, 133.1, 132.7, 132.6, 128.2, 127.9, 127.6, 127.2, 127.1, 126.4, 126.0, 123.5, 123.2, 119.6, 119.1, 67.4.


HRMS (ESI) Calc. for C₂₁H₁₆ClN₂O₃⁺ [M+H]⁺:379.0844; found:379.0849.



ethyl 2-oxo-8-(phenylethynyl)-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (4)

28.8 mg, 88% yield, yellow solid, MP = 197 – 198 °C, ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.04 (d, *J* = 2.4 Hz, 1H), 7.59 – 7.49 (m, 3H), 7.43 (dt, *J* = 5.1, 1.9 Hz, 3H), 7.26 – 7.20 (m, 1H), 7.15 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.08 (d, *J* = 1.5 Hz, 1H), 6.85 (d, *J* = 1.9 Hz, 1H), 4.25 (q, *J* = 7.1 Hz, 2H), 1.29 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 162.7, 160.7, 139.1, 131.4, 131.3, 129.1, 128.8, 127.7, 126.4, 125.7, 123.9, 122.4, 121.8, 118.4, 91.0, 88.6, 62.0, 14.0.

HRMS (ESI) Calc. for C₂₀H₁₇N₂O₃⁺ [M+H]⁺:333.1234; found:333,1225.





ethyl 8-(benzyloxy)-2-oxo-2,3-dihydro-1H-benzo[d][1,3]diazepine-4-carboxylate (5)

16.8 mg, 48% yield, yellow solid, MP = 193 – 194 °C, ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.05 (d, *J* = 2.2 Hz, 1H), 8.20 – 8.09 (m, 2H), 7.87 – 7.72 (m, 1H), 7.62 (t, *J* = 7.7 Hz, 2H), 7.51 (d, *J* = 2.1 Hz, 1H), 7.30 (d, *J* = 8.4 Hz, 1H), 6.96 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.93 (d, *J* = 1.7 Hz, 1H), 6.85 (d, *J* = 2.3 Hz, 1H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.31 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 164.73, 163.3, 161.4, 152.4, 140.7, 134.7, 132.5, 130.3, 129.5, 129.0, 127.5, 123.0, 119.4, 117.5, 113.9, 62.4, 14.5.



HRMS (ESI) Calc. for C₁₉H₁₇N₂O₅⁺ [M+H]⁺:353.1132; found:353.1129.

VI. Copies of ^1H and ^{13}C NMR Spectra


(1b)






(1ae)




(1af)




^1H NMR
(400 MHz, CDCl_3)




^{13}C NMR
(100 MHz, CDCl_3)









^{19}F NMR
(376 MHz, CDCl_3)





(3a)





(3b)





(3c)





(3d)




(3e)




(3f)








^{19}F NMR
(376 MHz, DMSO)




(3d)









^{19}F NMR
(376 MHz, CDCl_3)





(3h)





(3i)





(3j)





(3k)





(3)





(3m)





(3n)





(30)





(3p)





(3q)





(3r)





(3s)





(3t)





(3u)





(3v)





(3w)




(3x)





(3y)









(3z)





(3aa)





(3ab)





(3ac)





(3ad)



(4)




(5)



VII. X-ray Data

X-ray Data of 3e (CCDC: 2132509)



VIII. References

- [1] H.-M. Jin, B. Tian, X.-L. Song, J. Xie, M. Rudolph, F. Rominger, A. S. K. Hashmi, *Angew. Chem. Int. Ed.*, 2016, **55**, 12688.
- [2] P. Raju, G. G. Rajeshwaran, M. Nandakumar, A. K. Mohanakrishnan, *Eur. J. Org. Chem.*, 2015, **16**, 3513-3523.
- [3] J.-Y. Zhang, Y. Li, C.-F. Zhang, X.-N. Wang, J.-B. Chang, *Org. Lett.*, 2021, **23**, 2029–2035.
- [4] A. S. Golubev, A. F. Shidlovskii, A. S. Peregudov, N. D. Kagramanov, *Russ.Chem.Bull., Int.Ed.*, 2014, **63**, 2264-2270.
- [5] B.-L. Wen, N. Kazunari, S. Ken, N. Yoshiaki, *Angew. Chem. Int. Ed.*, 2019, **58**, 1168-1173.